All In Biotech

Drug Trial Radar · NCT00063999

Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF Versus Carboplatin/Paclitaxel in Patients With Stage III &Amp; IV or Recurrent Endometrial Cancer

Last checked: Nov 20, 2026Latest source record: Oct 19, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,381 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,381

Actual

Start

Aug 25, 2003

Primary completion

Jun 29, 2013

Study completion Jan 5, 2021

Sponsor

Lead sponsor
GOG FoundationResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI)
First posted
Jul 9, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized phase III trial compares how well two different combination chemotherapy regimens (doxorubicin hydrochloride, cisplatin, and paclitaxel versus carboplatin and paclitaxel) work in treating patients with endometrial cancer that is stage III-IV or has come back (recurrent). Drugs used in chemotherapy such as doxorubicin hydrochloride, cisplatin, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known which combination chemotherapy regimen is more effective in treating endometrial cancer.

Conditions

  • Recurrent Uterine Corpus Carcinoma
  • Stage IIIA Uterine Corpus Cancer AJCC v7
  • Stage IIIB Uterine Corpus Cancer AJCC v7
  • Stage IIIC Uterine Corpus Cancer AJCC v7
  • Stage IVA Uterine Corpus Cancer AJCC v7
  • Stage IVB Uterine Corpus Cancer AJCC v7

Interventions

  • CarboplatinDrug

    Given IV

  • CisplatinDrug

    Given IV

  • Doxorubicin HydrochlorideDrug

    Given IV

  • FilgrastimBiological

    Given SC

  • Laboratory Biomarker AnalysisOther

    Correlative studies

  • PaclitaxelDrug

    Given IV

  • PegfilgrastimBiological

    Given SC

  • Quality-of-Life AssessmentOther

    Ancillary studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Alive at Time of Last Follow-up.Time frame: Patients were assessed during treatment. Following completion of treatment, follow up was assessed every 3 months for 2 years, then every 6 months for 3 years and annually after for a maximum of 10 years.

Locations

650 sites in 3 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama

  • Clearview Cancer Institute

    Huntsville, Alabama

  • Mobile Infirmary Medical Center

    Mobile, Alabama

  • Providence Hospital

    Mobile, Alabama

  • Providence Alaska Medical Center

    Anchorage, Alaska

  • Mayo Clinic in Arizona

    Scottsdale, Arizona

  • Highlands Oncology Group PA - Fayetteville

    Fayetteville, Arkansas

  • Washington Regional Medical Center - Fayetteville

    Fayetteville, Arkansas

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Providence Saint Joseph Medical Center/Disney Family Cancer Center

    Burbank, California

  • John Muir Medical Center-Concord Campus

    Concord, California

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • Kaiser Permanente-Fremont

    Fremont, California

  • Saint Jude Medical Center

    Fullerton, California

  • Marin Cancer Care Inc

    Greenbrae, California

  • Long Beach Memorial Medical Center-Todd Cancer Institute

    Long Beach, California

  • Kaiser Permanente Los Angeles Medical Center

    Los Angeles, California

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California

  • Cedars Sinai Medical Center

    Los Angeles, California

  • UCLA / Jonsson Comprehensive Cancer Center

    Los Angeles, California

  • Community Hospital of Los Gatos

    Los Gatos, California

  • Doctors Medical Center

    Modesto, California

  • Memorial Medical Center

    Modesto, California

  • Kaiser Permanente-Oakland

    Oakland, California

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California

  • Stanford Cancer Institute Palo Alto

    Palo Alto, California

  • Kaiser Permanente-Redwood City

    Redwood City, California

  • Kaiser Permanente-Richmond

    Richmond, California

  • Kaiser Permanente-Roseville

    Roseville, California

  • Sutter Roseville Medical Center

    Roseville, California

  • Sutter Medical Center Sacramento

    Sacramento, California

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California

  • Kaiser Permanente-South Sacramento

    Sacramento, California

  • Kaiser Permanente - Sacramento

    Sacramento, California

  • Salinas Valley Memorial

    Salinas, California

  • University of California San Diego

    San Diego, California

  • Alvarado Hospital Medical Center

    San Diego, California

  • Zuckerberg San Francisco General Hospital

    San Francisco, California

  • Kaiser Permanente-San Francisco

    San Francisco, California

  • UCSF Medical Center-Mount Zion

    San Francisco, California

Showing 40 of 650 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.